PSMB2 Antibody
- Known as:
- PSMB2 Antibody
- Catalog number:
- csb-pa01385a0rb
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- CusAb
- Gene target:
- PSMB2 Antibody
Related genes to: PSMB2 Antibody
- Gene:
- PSMB2 NIH gene
- Name:
- proteasome subunit beta 2
- Previous symbol:
- -
- Synonyms:
- HC7-I
- Chromosome:
- 1p34.3
- Locus Type:
- gene with protein product
- Date approved:
- 1995-05-03
- Date modifiied:
- 2016-10-05
Related products to: PSMB2 Antibody
Related articles to: PSMB2 Antibody
- Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer-related death. Proteasome (PSM) is the main intracellular proteolytic system in higher eukaryotic cells. It has been reported to be involved in the tumor's onset, metabolism, and survival, and it has been recognized as a therapeutic target for many human cancers. The 20S proteasome subunits, specifically proteasome 20S subunit alpha 1 (PSMA1), proteasome 20S subunit alpha 5 (PSMA5), and proteasome 20S subunit beta 2 (PSMB2), are overexpressed in various malignancies, including HCC. Nevertheless, the exact role of these genes in HCC prognosis remains only partially understood. Moreover, a reliable predictive biomarker for HCC is essential for supporting the implementation of personalized therapies. Therefore, this study employed a comprehensive bioinformatics approach, integrating data from cBioPortal, Human Protein Atlas (HPA), Oncomine, STRING Viruses, Kaplan-Meier plotter, and other established high-throughput databases and tools. The current study thoroughly examined the expression levels, methylation, and genomic alterations of PSM and their correlation with tumor-infiltrating leukocytes. PSMA1, PSMA5, and PSMB2 are overexpressed in various cancers, including HCC, and their expression levels are associated with tumor grade and stage. The abundance of these genes is linked to diminished DNA methylation levels and genome alterations. Moreover, there was a significant association between the expression levels of these genes and poor prognosis and immune cell infiltration. In conclusion, this study proposes PSMA1, PSMA5, and PSMB2 as biomarkers for HCC. - Source: PubMed
Publication date: 2026/09/14
Islam BaitulXu WeiyeRehman Zaid UrZeng RuKhushafa ThekraYu HaiyangHuang Jufang - Triple-negative breast cancer (TNBC) represents one of the most aggressive and therapeutically challenging subtypes of breast cancer, characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression. Due to the lack of specific molecular targets, treatment options for TNBC remain limited, resulting in higher recurrence rates, increased metastatic potential, and poorer overall survival compared with other breast cancer subtypes. Therefore, identifying novel therapeutic targets and potential bioactive compounds is essential for improving TNBC management. In this study, an integrative systems biology and computational pharmacology approach was employed to explore potential molecular targets underlying oxidative stress-mediated mechanisms in TNBC and to identify plant-derived compounds with therapeutic relevance. Transcriptomic analysis was performed to identify differentially expressed genes between TNBC and normal ductal tissues, followed by weighted gene coexpression network analysis to detect disease-associated gene modules. Intersection analysis integrating phytochemical targets, oxidative stress-related genes, and network-derived candidate genes identified seven potential key genes. Functional enrichment analysis revealed that these genes were mainly involved in oxidative stress response, DNA repair mechanisms, proteasome activity, and cell cycle regulation pathways. Immune infiltration analysis further demonstrated significant remodeling of the tumor immune microenvironment in TNBC. Machine learning algorithms identified PSMB2 as the most robust core gene associated with TNBC. Finally, molecular docking analysis demonstrated favorable binding interactions between the predicted target protein and several phytochemical compounds, particularly 6-gingerol, curcumin, and demethoxycurcumin. These findings highlight the potential of integrating computational approaches with natural product screening to identify novel therapeutic strategies for TNBC. - Source: PubMed
Publication date: 2026/08/21
Alshabrmi Fahad M - Glioblastoma multiforme (GBM), a highly aggressive primary brain malignancy, is characterized by its accelerated development, refractoriness to therapy, and dismal prognosis. The proteasome subunit β2 (PSMB2), a catalytic unit of the 20S proteasome, has been linked to tumorigenesis across multiple malignancies; however, its signaling and therapeutic relevance in GBM remains incompletely defined. U87 and U251 GBM cells were engineered to overexpress (OE-PSMB2) or silence (Sh-PSMB2) PSMB2. We assessed the function of PSMB2 in GBM cell proliferation, migration, and related phenotypes, and further examined its association with the PTEN/PI3K/AKT signaling axis at both transcriptomic and protein levels. A xenograft model was conducted in the intracranial setting where the therapeutic efficacy of PSMB2 silencing, when used together with temozolomide (TMZ), was assessed. PSMB2 overexpression stimulated GBM cell proliferation, migration, and invasion, and PSMB2 silencing inhibited these phenotypes and promoted apoptosis. RNA-seq showed that PI3K/AKT pathway was enriched in Sh-PSMB2 cells. Protein-level analysis showed that PSMB2 expression was inversely associated with PTEN abundance and was accompanied by altered PI3K/AKT pathway activity. PSMB2 silencing decreased tumor burden and increased survival in vivo, and the combination of PSMB2 silencing and TMZ produced the greatest therapeutic effect. PSMB2 may function as a tumor-promoting regulator in GBM and is associated with PTEN/PI3K/AKT pathway modulation. Targeting PSMB2 suppressed tumor progression and enhanced the therapeutic response to TMZ in vivo, suggesting that PSMB2 may represent a potential therapeutic target for GBM. - Source: PubMed
Publication date: 2026/07/20
Tan ZiLongTang XiaolongChen ZhuoZhong YutingYe QinglinLi MinHe Wei - Sepsis is a life-threatening systemic inflammatory syndrome with limited targeted therapeutic options. Handelin, a natural compound derived from Chrysanthemum indicum, exhibits anti-inflammatory activity, yet its direct targets and protective mechanisms in sepsis remain unclear. - Source: PubMed
Publication date: 2026/03/19
Chen DexiuZhang QianWu YuanxinHu YingchunChen Muhu - Neddylation modifications in immune and tumor cells are linked to poor tumor prognosis. This study identifies prognostic genes associated with neddylation-related genes (NRGs) in colorectal cancer (CRC) using single-cell and spatial transcriptome (ST) sequencing, aiming to advance CRC treatment strategies. - Source: PubMed
Publication date: 2025/12/24
Zhu ZimingZhang XinyueWang SongHuang YunsiHan XuedongLai DongpingYao XinLan WeixuanNong HuiZeng WenbinMo YanhuaXu Ri'anZhang Tao